Gold Flora Corp. (CBOE: GRAM) (OTCQB: GRAM) is also obviously floundering, with $18.8 million in losses for the most recent ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...

The Toronto-based drugmaker's revenue held steady, helped by stronger performance from its Colombian operations.

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

Cannabis tax rates in California are going up. Again. The state’s 15% excise tax rate on all cannabis products is set to ...

Ditching cannabis growing tech for hemp-based drinks marks a new era for the firm under its new GTI leadership.

The CBD maker said state-level changes in hemp laws as public health concerns rise are impeding attempts to expand its retail ...

Tilt also reported a net loss of $12.6 million in the quarter versus a net loss of $8.7 million in the prior year period. At ...

The firm expects to report its 12-month phase 2 data next week, with topline results from a phase 3 trial anticipated in 2026 ...